

Complera

(emtricitabine/rilpivirine/tenofovir disoproxil fumarate)

Manufacturer:
Gilead

FDA Approval Date:
August 10, 2011

For treatment of:
HIV-1 Infection

Dosage:
Oral Tablet



Questions?

julia.maloney@ipc-inc.com
636-614-1344

**For more information
about IPC and our
services:**

www.ipc-inc.com

IPC's Recommendation

Implement a Prior Authorization program to ensure Complera is used to treat an FDA approved condition, for patients over the age of 19, and no other HIV medications are being dispensed.



Marketing Information from Manufacturer (key points):

The FDA approved Complera as a first line treatment for once-a-day dosing for patients with HIV-1 infection and who have not yet begun treatment with any other HIV medications.

Complera is a combination of three related drugs, Edurant, Viread and Emtriva. All three drugs can still be purchased individually for use in combination with other HIV drugs however because these three medications contain the same or similar active ingredients as Complera they should not be taken with Complera.

Benefits and Concerns:

Primary issue with treatment for HIV is patient compliance with complicated therapy. Certain patients may benefit from a combination product that simplifies dosing regimen. Like all HIV drugs, Complera can have serious side effective, and should not be taken with other HIV medicines, Anti-Seizure medications, Anti-Tuberculosis, Proton Pump Inhibitors, more than one steroid medication or St. Johns Wart (or any Herbal product containing St. John's Wart).

This information is being provided for informational purposes only. All decisions about prescription drugs are between the member and their physician or other health care provider.